Current Urology Reports

, 18:75 | Cite as

Is There a Role for Preoperative 5 Alpha Reductase Inhibitors in Reducing Prostate Vascularity and Blood Loss?

Benign Prostatic Hyperplasia (K McVary, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Benign Prostatic Hyperplasia


Benign prostatic hyperplasia (BPH) and the related medical problems are a major burden as health care costs and as a cause of patient morbidity. The introduction of medical therapy largely offered an alternative to surgical therapy, and these medications have been linked with multiple positive BPH-related outcomes. With ubiquitous use, however, a variety of adverse side effects and unsupported claims to these medications have been reported both in scientific literature and popular press. The use of 5 alpha reductase inhibitors (5ARIs) to reduce recurrent bleeding due to BPH is a reasonable option for men with recurrent trips to the physician or hospital. After a largely anecdotal report of their use in the preoperative period to reduce bleeding during BPH surgery, there was interest in the use of 5ARIs for this indication considering the effusive bleeding that can occur during BPH-related surgery, a dreaded and not uncommon complication. While the pathophysiology for the use of 5ARI to reduce BPH-related bleeding is sound, the actual clinical outcomes still require scrutiny to determine if the efficacy is both scientifically valid and clinically significant. This report will review the current literature on this topic and make attempts to determine if the use of a 5ARI before BPH-related surgery should be encouraged.


5 Alpha reductase inhibitor Benign prostatic hyperplasia Prostate surgery Finasteride Dutasteride 


Compliance with Ethical Standards

Conflict of Interest

Matthew Bruha declares no potential conflicts of interest.

Charles Welliver reports honorarium from the American Society of Andrology, a paid reviewer for BMJ and Oakstone Publishing, and a consultant for Coloplast.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    American Urological Association. Management of Benign Prostatic Hyperplasia (BPH). 2014. Accessed 5 May 2017.
  2. 2.
    Welliver C, McVary KT. Minimally invasive and endoscopic management of benign prostatic hyperplasia. In: Wein AJ, Kavoussi LR, Partin AW, Peters CA, editors. Campbell-Walsh urology. 11th ed. Philadelphia, PA: Elsevier; 2015.Google Scholar
  3. 3.
    Hagerty JA, Ginsberg PC, Harmon JD, Harkaway RC. Pretreatment with finasteride decreases perioperative bleeding associated with transurethral resection of the prostate. Urology. 2000;55(5):684–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Foley SJ, Soloman LZ, Wedderburn AW, Kashif KM, Summerton D, Basketter V, et al. A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride. J Urol. 2000;163(2):496–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Roehrborn CG, McConnell JD, Lieber M, Kaplan S, Geller J, Malek GH, et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology. 1999;53(3):473–80.CrossRefPubMedGoogle Scholar
  6. 6.
    Roehrborn CG, Bruskewitz R, Nickel JC, McConnell JD, Saltzman B, Gittelman MC, et al. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia. J Urol. 2004;171(3):1194–8. doi: 10.1097/01.ju.0000112918.74410.94.CrossRefPubMedGoogle Scholar
  7. 7.
    Fwu CW, Eggers PW, Kirkali Z, McVary KT, Burrows PK, Kusek JW. Change in sexual function in men with lower urinary tract symptoms/benign prostatic hyperplasia associated with long-term treatment with doxazosin, finasteride and combined therapy. J Urol. 2014;191(6):1828–34. doi: 10.1016/j.juro.2013.12.014.CrossRefPubMedGoogle Scholar
  8. 8.
    Welliver C, Butcher M, Potini Y, McVary KT. Impact of alpha blockers, 5-alpha reductase inhibitors and combination therapy on sexual function. Curr Urol Rep. 2014;15(10):441. doi: 10.1007/s11934-014-0441-2.CrossRefPubMedGoogle Scholar
  9. 9.
    Cunha GR, Chung LW, Shannon JM, Taguchi O, Fujii H. Hormone-induced morphogenesis and growth: role of mesenchymal-epithelial interactions. Recent Prog Horm Res. 1983;39:559–98.PubMedGoogle Scholar
  10. 10.
    Chung LW, Gleave ME, Hsieh JT, Hong SJ, Zhau HE. Reciprocal mesenchymal-epithelial interaction affecting prostate tumour growth and hormonal responsiveness. Cancer Surv. 1991;11:91–121.PubMedGoogle Scholar
  11. 11.
    Tanner MJ, Welliver RC Jr, Chen M, Shtutman M, Godoy A, Smith G, et al. Effects of androgen receptor and androgen on gene expression in prostate stromal fibroblasts and paracrine signaling to prostate cancer cells. PLoS One. 2011;6(1):e16027. doi: 10.1371/journal.pone.0016027.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int. 1999;56(3):794–814. doi: 10.1046/j.1523-1755.1999.00610.x.CrossRefPubMedGoogle Scholar
  13. 13.
    Ravindranath N, Wion D, Brachet P, Djakiew D. Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. J Androl. 2001;22(3):432–43.PubMedGoogle Scholar
  14. 14.
    Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260(5112):1317–20.CrossRefPubMedGoogle Scholar
  15. 15.
    Linehan WM, Pinto PA, Srinivasan R, Merino M, Choyke P, Choyke L, et al. Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin Cancer Res. 2007;13(2 Pt 2):671s–9s. doi: 10.1158/1078-0432.CCR-06-1870.CrossRefPubMedGoogle Scholar
  16. 16.
    Joseph IB, Nelson JB, Denmeade SR, Isaacs JT. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res. 1997;3(12 Pt 1):2507–11.PubMedGoogle Scholar
  17. 17.
    Sordello S, Bertrand N, Plouet J. Vascular endothelial growth factor is up-regulated in vitro and in vivo by androgens. Biochem Biophys Res Commun. 1998;251(1):287–90. doi: 10.1006/bbrc.1998.9328.CrossRefPubMedGoogle Scholar
  18. 18.
    Aslan G, Cimen S, Yorukoglu K, Tuna B, Sonmez D, Mungan U, et al. Vascular endothelial growth factor expression in untreated and androgen-deprived patients with prostate cancer. Pathol Res Pract. 2005;201(8–9):593–8. doi: 10.1016/j.prp.2005.07.003.CrossRefPubMedGoogle Scholar
  19. 19.
    Kravchick S, Cytron S, Mamonov A, Peled R, Linov L. Effect of short-term dutasteride therapy on prostate vascularity in patients with benign prostatic hyperplasia: a pilot study. Urology. 2009;73(6):1274–8. doi: 10.1016/j.urology.2008.08.461.CrossRefPubMedGoogle Scholar
  20. 20.
    Levine AC, Liu XH, Greenberg PD, Eliashvili M, Schiff JD, Aaronson SA, et al. Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts. Endocrinology. 1998;139(11):4672–8. doi: 10.1210/endo.139.11.6303.CrossRefPubMedGoogle Scholar
  21. 21.
    Franck-Lissbrant I, Haggstrom S, Damber JE, Bergh A. Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. Endocrinology. 1998;139(2):451–6. doi: 10.1210/endo.139.2.5683.CrossRefPubMedGoogle Scholar
  22. 22.
    Lekas E, Engstrand C, Bergh A, Damber JE. Transient ischemia induces apoptosis in the ventral prostate of the rat. Urol Res. 1999;27(3):174–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Marshall S, Narayan P. Treatment of prostatic bleeding: suppression of angiogenesis by androgen deprivation. J Urol. 1993;149(6):1553–4.CrossRefPubMedGoogle Scholar
  24. 24.
    Ku JH, Shin JK, Cho MC, Myung JK, Moon KC, Paick JS. Effect of dutasteride on the expression of hypoxia-inducible factor-1alpha, vascular endothelial growth factor and microvessel density in rat and human prostate tissue. Scand J Urol Nephrol. 2009;43(6):445–53. doi: 10.3109/00365590903337896.CrossRefPubMedGoogle Scholar
  25. 25.
    Haggstrom S, Torring N, Moller K, Jensen E, Lund L, Nielsen JE, et al. Effects of finasteride on vascular endothelial growth factor. Scand J Urol Nephrol. 2002;36(3):182–7. doi: 10.1080/003655902320131848.CrossRefPubMedGoogle Scholar
  26. 26.
    Berardinis EDAG, Busetto GM, Gentile V, Silverio FD, et al. Reduced intraoperative bleeding during transurethral resection of the prostate: evaluation of finasteride, vascular endothelial growth factor, and CD34. Curr Prostate Rep. 2005;6:123–7.CrossRefGoogle Scholar
  27. 27.
    Pareek G, Shevchuk M, Armenakas NA, Vasjovic L, Hochberg DA, Basillote JB, et al. The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients. J Urol. 2003;169(1):20–3. doi: 10.1097/01.ju.0000039923.75777.91.CrossRefPubMedGoogle Scholar
  28. 28.
    Sutton MT, Yingling M, Vyas A, Atiemo H, Borkowski A, Jacobs SC, et al. Finasteride targets prostate vascularity by inducing apoptosis and inhibiting cell adhesion of benign and malignant prostate cells. Prostate. 2006;66(11):1194–202. doi: 10.1002/pros.20444.CrossRefPubMedGoogle Scholar
  29. 29.
    Jia G, Heverhagen JT, Polzer H, Jacko RV, Liang J, Zhang J, et al. Dynamic contrast enhanced magnetic resonance imaging as a biological marker to noninvasively assess the effect of finasteride on prostatic suburethral microcirculation. J Urol. 2006;176(5):2299–304. doi: 10.1016/j.juro.2006.07.056.CrossRefPubMedGoogle Scholar
  30. 30.
    Deering RE, Bigler SA, Brown M, Brawer MK. Microvascularity in benign prostatic hyperplasia. Prostate. 1995;26(3):111–5.CrossRefPubMedGoogle Scholar
  31. 31.
    Hochberg DA, Basillote JB, Armenakas NA, Vasovic L, Shevchuk M, Pareek G, et al. Decreased suburethral prostatic microvessel density in finasteride treated prostates: a possible mechanism for reduced bleeding in benign prostatic hyperplasia. J Urol. 2002;167(4):1731–3.CrossRefPubMedGoogle Scholar
  32. 32.
    Donohue JF, Sharma H, Abraham R, Natalwala S, Thomas DR, Foster MC. Transurethral prostate resection and bleeding: a randomized, placebo controlled trial of role of finasteride for decreasing operative blood loss. J Urol. 2002;168(5):2024–6. doi: 10.1097/01.ju.0000028607.29093.56.CrossRefPubMedGoogle Scholar
  33. 33.
    Lund L, Moller Ernst-Jensen K, Torring N, Erik Nielsen J. Impact of finasteride treatment on perioperative bleeding before transurethral resection of the prostate: a prospective randomized study. Scand J Urol Nephrol. 2005;39(2):160–2. doi: 10.1080/00365590510007694.CrossRefPubMedGoogle Scholar
  34. 34.
    Sandfeldt L, Bailey DM, Hahn RG. Blood loss during transurethral resection of the prostate after 3 months of treatment with finasteride. Urology. 2001;58(6):972–6.CrossRefPubMedGoogle Scholar
  35. 35.
    • Hahn RG, Fagerstrom T, Tammela TL, Van Vierssen TO, Beisland HO, Duggan A, et al. Blood loss and postoperative complications associated with transurethral resection of the prostate after pretreatment with dutasteride. BJU Int. 2007;99(3):587–94. doi: 10.1111/j.1464-410X.2006.06619. This study is the largest and most rigorous study examining the use of a 5ARI in men. Clinical outcomes were not convincingly improved through the use of Dutasteride CrossRefPubMedGoogle Scholar
  36. 36.
    Kaplan SA, Lee JY, Meehan AG, Kusek JW, Group MR. Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate: data from the MTOPS trial. J Urol. 2011;185(4):1369–73. doi: 10.1016/j.juro.2010.11.060.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Busetto GM, Giovannone R, Antonini G, Rossi A, Del Giudice F, Tricarico S, et al. Short-term pretreatment with a dual 5alpha-reductase inhibitor before bipolar transurethral resection of the prostate (B-TURP): evaluation of prostate vascularity and decreased surgical blood loss in large prostates. BJU Int. 2015;116(1):117–23. doi: 10.1111/bju.12917.CrossRefPubMedGoogle Scholar
  38. 38.
    • Zhu YP, Dai B, Zhang HL, Shi GH, Ye DW. Impact of preoperative 5alpha-reductase inhibitors on perioperative blood loss in patients with benign prostatic hyperplasia: a meta-analysis of randomized controlled trials. BMC Urol. 2015;15:47. doi: 10.1186/s12894-015-0043-4. This meta-analysis of controlled trials found fairly minor effects of 5ARI but included studies with heterogeneous study designs and varied outcomes CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med. 1992;327(17):1185–91. doi: 10.1056/NEJM199210223271701.CrossRefPubMedGoogle Scholar
  40. 40.
    Aminsharifi A, Salehi A, Noorafshan A, Aminsharifi A, Alnajar K. Effect of preoperative finasteride on the volume or length density of prostate vessels, intraoperative, postoperative blood loss during and after monopolar transurethral resection of prostate: a dose escalation randomized clinical trial using stereolog methods. Urol J. 2016;13(1):2562–8.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  1. 1.Albany Medical CollegeAlbanyUSA
  2. 2.Albany Stratton Veterans Affairs Medical CenterAlbanyUSA

Personalised recommendations